Clinical Trial Update: Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Metastatic Colorectal Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of gemcitabine and docetaxel in relapsed or refractory metastatic colorectal adenocarcinoma was terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Adenocarcinoma

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Metastatic Colorectal Adenocarcinoma | Phase 2 | Status: TERMINATED | Results posted: 2022-08-10